Allianz Asset Management’s Beam Therapeutics BEAM Stock Holding History

Allianz Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$381K	Buy	11,100 +2,300	+26%	+$69.4K	﹤0.01%	2019
2026 Q1	$210K	Buy	+8,800	New	+$244K	﹤0.01%	1938
2022 Q1	–	Sell	-15,565	Closed	-$1.25M	–	2415
2021 Q4	$1.25M	Sell	15,565 -2,950	-16%	-$253K	﹤0.01%	1808
2021 Q3	$1.61M	Buy	18,515 +7,570	+69%	+$761K	﹤0.01%	1734
2021 Q2	$1.41M	Sell	10,945 -1,345	-11%	-$107K	﹤0.01%	1603
2021 Q1	$984K	Sell	12,290 -3,790	-24%	-$361K	﹤0.01%	1647
2020 Q4	$1.31M	Buy	+16,080	New	+$791K	﹤0.01%	1424

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Allianz Asset Management's BEAM Position: Q2 2026 in Review

Allianz Asset Management increased its Beam Therapeutics (BEAM) stake by 26% in Q2 2026, buying an estimated $69.4K and bringing the position to 11,100 shares worth $381K. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

Allianz Asset Management first reported a position in BEAM in Q4 2020 and has held it in 7 quarters since. The position peaked at $1.61M in Q3 2021. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Allianz Asset Management held 11,100 shares of Beam Therapeutics worth $381K as of Q2 2026.
Allianz Asset Management bought 2,300 Beam Therapeutics shares in Q2 2026, an estimated $69.4K.
Beam Therapeutics made up ﹤0.01% of Allianz Asset Management's portfolio in Q2 2026, its #2019 holding.
Allianz Asset Management first reported a position in Beam Therapeutics in Q4 2020 and has held it in 7 quarters since.
Allianz Asset Management's Beam Therapeutics position peaked at $1.61M in Q3 2021.
278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Allianz Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.